Company Update | Bumrungrad Hospital (BH TB/BUY/Bt178.00/Target: Bt214.00) We upgrade BH to BUY with a target price of Bt214.00. BH’s outlook has improved with its strong 3Q25 performance and positive sentiment drivers. BH did not join the Kuwait conference and will not receive any negative impact. BH focuses on high-paying foreign and inpatient clients, insulating it from the new pricing measures. Net profit is expected at Bt2.5b (+4.6% yoy), supported by recovering Middle Eastern demand. Wit...
                                                                                Top Stories Company Update | Asset World Corporation (AWC TB/BUY/Bt2.08/Target: Bt3.30) AWC’s Jurassic World at Asiatique, launched in Aug 25 with Bt1.4b capex, exceeds targets with 2,400-2,800 visitors and Bt2m daily revenue. The park attracted mainly Thai families and school groups, with rising foreign visitors, particularly from China and Korea. It boosted Asiatique’s retail traffic, strengthening rental demand. AWC has planned periodic content refreshes to sustain interest and may replica...
                                                                                Greater China Economics | Inflation September’s CPI inflation improved slightly to -0.3% yoy (+0.1ppt), with core CPI reaching a ytd high of 1.0% yoy. However, food prices remained weak (-4.4% yoy), led by a 17% yoy fall in pork prices. PPI deflation eased to -2.3% yoy (+0.6ppt), with broad recovery in mining and quarrying and raw metal materials. Looking ahead, look out for improvement in consumer goods PPI inflation, which should be indicative of a sustainable improvement in pricing power....
                                                                                Greater China Sector Update | Automobile China’s PV sales rebounded last week, with PEV growth surging from below 5% to over 30% due to subsidies and new models. Geely and XPeng led, while BYD and Li Auto lagged. Vehicle exports rose 26% yoy in August, driven by gains in the EU, Africa, and Middle East. Maintain MARKET WEIGHT. Top BUYs: CATL (target price raised to Rmb520) and Geely. Top SELLs: BYD and Li Auto. Sector Update | Healthcare Falling interest rates are expected to significant...
                                                                                A director at Bumrungrad Hospital Public Company Limited bought 100,000 shares at 180.250THB and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
                                                                                The tone at BH’s 2Q25 analyst meeting was positive. Management provided a positive development update on the Kuwaiti patient issue, indicating that it should be resolved soon. The 3Q25 guidance is also promising as last year’s base will no longer include the Kuwait patient portion and revenue intensity is expected to improve. We are more positive on BH, but the timeline and the magnitude of Kuwaiti patients’ return is still uncertain, and the market has already priced this in. Maintain HOLD...
                                                                                KEY HIGHLIGHTS Sector Property Expect earnings to recover in 2Q25, but 2H25 outlook remains uncertain. Update Bumrungrad Hospital (BH TB/HOLD/Bt176.50/Target: Bt185.00) Cautiously optimistic in 2H25. Kasikorn Bank (KBANK TB/BUY/Bt160.50/Target: Bt192.00 To increase dividend policy from 25% to 50% and guide for potential capital management.
                                                                                GREATER CHINA Strategy Alpha Picks: August Conviction Calls: Add JBM Healthcare and Lenovo to our BUY list. Take profit on CATL, Han’s Laser, KE Holdings and Longfor. INDONESIA Strategy 1H25 Results Recap: Among the 40 stocks under our coverage that have announced their results, 25% beat forecasts, 39% were in line and 35% were below expectations. Results Indofood CBP (ICBP IJ/BUY/Rp9,550/Target: Rp13,800): 1H25: Core profit in line with our expectation. MALAYSIA Update Alpha IVF (ALPHA MK/BUY...
                                                                                BH is expected to report a net profit of Bt1.7b (-11.4% yoy, -1.3% qoq) in 2Q25. Top-line should be weak at Bt6.0b (-5.0% yoy, -2.5% qoq), as it continues to be pressured by the slower return of Middle Eastern patients and the Thai-Cambodia conflict which will likely lead to a slowdown in Cambodian patient arrivals. We remain cautious on BH as there are still several overhangs related to foreign patient markets that could cause a further decline in revenue intensity just like in 1Q25. Maint...
                                                                                
                                                                                GREATER CHINA Update Xtep International Holdings (1368 HK/BUY/HK$5.34/Target: HK$8.00) Confident in achieving full-year targets; Saucony on track to reach mid-term goal. INDONESIA Small/Mid Cap Highlights Bank KB Bukopin (BBKP IJ/NOT RATED/Rp60) Turnaround hinges on CoF reduction. MALAYSIA Update Kuala Lumpur Kepong (KLK MK/HOLD/RM20.46/Target: RM20.50) We expect 3QFY25 results to come in flat qoq, supported by firmer plantation output and lower forex ...
                                                                                GREATER CHINA Economics Economic Activity Mixed bag for May. Sector Property Property market weakens further in May 25, with diverging city-tier performance. INDONESIA Initiate Coverage Bumi Resources Minerals (BRMS IJ/BUY/Rp454/Target: Rp610) Soaring to new heights; initiate coverage with BUY. MALAYSIA Update Press Metal ...
                                                                                GREATER CHINA Sector Macau Gaming: Apr 25 GGR beat expectations; May Day Golden Week visitor arrivals expected to grow 4% yoy. Results ASMPT (522 HK/BUY/HK$52.20/Target: HK$68.00): 1Q25: Earnings disappoint; mainstream tools recovering in 2025 but visibility remains low. Maintain BUY. China Tourism Group Duty Free (601888 CH/BUY/Rmb63.40/Target: Rmb70.80): 1Q25: Core net profit down 16% yoy; sequential improvement in Hainan duty-free sales. Ganfeng Lithium (1772 HK/BUY/HK$18.94/Target: HK$30.00)...
                                                                                The tone at BH’s 1Q25 analyst meeting was negative. Management still does not expect a rebound in hospital revenue as a result of the earthquake in Mar 25. The drop in revenue intensity in 1Q25 could become a concern if it becomes a recurring trend. Despite the positive development in Saudi Arabia and Bangladesh, we are less optimistic on BH as it lacks a substantial catalyst to improve its earnings. Downgrade to HOLD. Target price: Bt178.00.
                                                                                KEY HIGHLIGHTS Sector Property 1Q25 earnings under pressure; recovery outlook remains uncertain. Update Asset World Corporation (AWC TB/BUY/Bt2.20/Target: Bt3.30) Expect strong earnings growth in 1Q25. Bumrungrad Hospital (BH TB/HOLD/Bt168.50/Target: Bt178.00) Less optimistic on foreign patient numbers. Downgrade to HOLD. Siam Cement (SCC TB/HOLD/Bt160.00/Target: Bt160.00) Timeline for the LSP project to resume operations remains uncertain.
                                                                                BH reported a net profit of Bt1.73b (-12.6% yoy, -8.9% qoq) in 1Q25, which is in line with our and consensus estimates. The high base last year and the earlier timing of Ramadan this year caused top-line to drop by 6.1% yoy. Growth in revenue from Thai patients was weak at 1.3% yoy and was not sufficient to compensate for the shortfall in foreign patient revenue. We are more optimistic about BH’s 2Q25 outlook as the impact from Ramadan was already realised in 1Q25. Maintain BUY. Target pric...
                                                                                KEY HIGHLIGHTS Sector Banking 1Q25: Results beat; banks prioritise less on loan growth. Downgrade to MARKET WEIGHT. Results Bumrungrad Hospital (BH TB/BUY/Bt169.00/Target: Bt232.00) 1Q25: Weak results in line with expectations. Update Thai Foods Group (TFG TB/BUY/Bt5.05/Target: Bt6.70) Expect record-high earnings in 1Q25 and 2Q25. Thanachart Capital (TCAP TB/HOLD/Bt47.00/Target: Bt48....
                                                                                GREATER CHINA Results Aier Eye Hospital Group (300015 CH/BUY/Rmb12.72/Target: Rmb17.80) 2024: Satisfactory results; expects strong recovery in 2025. Upgrade to BUY. Ningbo Tuopu Group Co (601689 CH/BUY/Rmb50.96/Target: Rmb83.00) 4Q24: Earnings up 38.5% yoy, in line. Maintain BUY with target price unchanged at Rmb83.00. TAL Educational Group (TAL US/BUY/US$9.36/Target: US$14.00) 4QFY25: Earnings miss amid ramped-up investments in AI-powered learning. INDONESIA Sector Telecommun...
                                                                                We expect BH to report a net profit of Bt1.7b in 1Q25 (-13.2% yoy, -9.4% qoq). Top-line should be weak at Bt6.1b (-6.5% yoy, -5.6% qoq) due to the high base last year and the earlier timing of Ramadan this year. As a result, the expected decrease in Middle Eastern patient volume should also lead to a yoy margin contraction. We expect the 2Q25 outlook to improve, as a yoy growth will come off a more normalised base in 2Q24. Maintain BUY. Target price: Bt232.00.
                                                                                KEY HIGHLIGHTS Results Bangkok Bank (BBL TB/HOLD/Bt146.50/Target: Bt154.00) 1Q25: Results beat expectations; investment gain boosted the bottom line. TISCO Financial Group (TISCO TB/HOLD/Bt100.00/Target: Bt94.00) 1Q25: Results in line; revises down 2025 credit cost target to 100bp. Update Bumrungrad Hospital (BH TB/BUY/Bt168.00/Target: Bt232.00) Expect weak 1Q25 earnings due to margin pressure.
    
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.